SynthesisPsychopharmacology2012
Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex.
Synthesis in Psychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.Psychopharmacology · 2022Pooled it
- Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants.The international journal of neuropsychopharmacology · 2023Trial
- Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.Psychopharmacology · 2018Trial
- No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA.European journal of clinical pharmacology · 2018Trial
- Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects.Psychopharmacology · 2018Trial
- Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects.PloS one · 2018Trial
- Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.Clinical pharmacokinetics · 2017Trial
- Human Pharmacology of Mephedrone in Comparison with MDMA.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Trial
- Empathic accuracy and oxytocin after tryptophan depletion in adults at risk for depression.Psychopharmacology · 2016Trial
- The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity.Biological psychiatry · 2015Trial
- Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans.The international journal of neuropsychopharmacology · 2015Trial
- Intimate insight: MDMA changes how people talk about significant others.Journal of psychopharmacology (Oxford, England) · 2015Trial
- MDMA enhances emotional empathy and prosocial behavior.Social cognitive and affective neuroscience · 2014Trial
- Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans.Psychoneuroendocrinology · 2014Trial
- Effects of MDMA and Intranasal oxytocin on social and emotional processing.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Trial
- Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use.Molecular psychiatry · 2026Review
- Phasic, Event-Related Transcutaneous Auricular Vagus Nerve Stimulation Modifies Behavioral, Pupillary, and Low-Frequency Oscillatory Power Responses.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Article
- Social anxiety and MDMA-assisted therapy investigation: a novel clinical trial protocol.Frontiers in psychiatry · 2023Article
- Distribution of Pupil Size and Associated Factors: Results from the Population-Based Gutenberg Health Study.Journal of ophthalmology · 2022Article
- Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment.Journal of psychopharmacology (Oxford, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationalePupillometry can be used to characterize autonomic drug effects.
objectiveThis study was conducted to determine the autonomic effects of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), administered alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin, on pupillary function.
methodsInfrared pupillometry was performed in five placebo-controlled randomized studies. Each study included 16 healthy subjects (eight men, eight women) who received placebo-MDMA (125 mg), placebo-placebo, pretreatment-placebo, or pretreatment-MDMA using a crossover design.
resultsMDMA produced mydriasis, prolonged the latency, reduced the response to light, and shortened the recovery time. The impaired reflex response was associated with subjective, cardiostimulant, and hyperthermic drug effects and returned to normal within 6 h after MDMA administration when plasma MDMA levels were still high. Mydriasis was associated with changes in plasma MDMA concentration over time and longer-lasting. Both reboxetine and duloxetine interacted with the effects of MDMA on pupillary function. Clonidine did not significantly reduce the mydriatic effects of MDMA, although it produced miosis when administered alone. Carvedilol and doxazosin did not alter the effects of MDMA on pupillary function.
conclusionsThe MDMA-induced prolongation of the latency to and reduction of light-induced miosis indicate indirect central parasympathetic inhibition, and the faster recovery time reflects an increased sympathomimetic action. Both norepinephrine and serotonin mediate the effects of MDMA on pupillary function. Although mydriasis is lasting and mirrors the plasma concentration-time curve of MDMA, the impairment in the reaction to light is associated with the subjective and other autonomic effects of MDMA and exhibits acute tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.